301206 Shandong Sanyuan Biotechnology
- 25.82
- +0.05+0.19%
Shandong Sanyuan Biotechnology News
Sanyuan Biotech (301206.SZ): High-quality stevia products have been officially sold and are currently being actively promoted
Gelonghui, May 22丨An investor asked Sanyuan Biotech (301206.SZ) on the investor interactive platform, “When exactly can Sanyuan Biotech's steviol glycoside products be officially sold?” The company replied that the company's high-quality stevia products have been officially sold and are currently being actively promoted.
Sanyuan Biotech (301206.SZ) plans to pay 2.5 yuan for 10 shares to be deducted from interest on May 29
Zhitong Finance App News, Sanyuan Biotech (301206.SZ) announced that the company's 2023 equity distribution plan: 2.5 yuan (tax included) for every 10 shares to all shareholders; the exclusion date is: May 29, 2024.
Sanyuan Biology (301206.SZ): The company's sugar substitute products are mainly used in the food, beverage and health products industry
Gelonghui, May 14 | Sanyuan Biotech (301206.SZ) said on the investor interactive platform that the company's sugar substitute products are mainly used in the food, beverage and health products industries. For any customer using these products in artificial meat related industries, it is recommended to directly consult the relevant company or industry department to obtain accurate information.
Sanyuan Biology (301206.SZ): Actively participating in synthetic biology's technological innovation in the field of functional sugar
Gelonghui, May 14 | Sanyuan Biology (301206.SZ) said on the investor interactive platform that the company is actively participating in synthetic biology's technological innovation in the field of functional sugar, using related technology to develop new products and optimize production processes. Once the technology is mature, it is expected that the company's main products will plan to use related technology.
Sanyuan Biology (301206.SZ): All preparations have been made to produce small packages of sugar
Gelonghui May 13 丨 Some investors asked Sanyuan Biotech (301206.SZ) on the investor interactive platform, “Does the company have any plans for erythritol to enter supermarkets?” The company replied that small packages of erythritol and its mixed sugar as table sugar are already very common in supermarkets in developed countries such as Europe and the US, and the domestic market is still in its early stages. The company has made all preparations to produce small packages of sugar, and will actively seek market opportunities in supermarkets when the time is ripe.
Sanyuan Biology (301206.SZ): Currently, the annual production capacity of allodonose is 2,000 tons of crystals (3,000 tons of liquid)
Gelonghui, May 13 | Sanyuan Biotech (301206.SZ) said on the investor interactive platform that the company currently produces 2,000 tons of crystals (3,000 tons of liquid) per year. Existing production capacity can no longer meet customer needs. The company is stepping up construction of new production capacity. It plans to first expand production to 10,000 tons per year, then further expand production to 20,000 tons per year according to market conditions.
After Leaping 27% Shandong Sanyuan Biotechnology Co.,Ltd. (SZSE:301206) Shares Are Not Flying Under The Radar
Shandong Sanyuan Biotechnology Co.,Ltd. (SZSE:301206) shares have continued their recent momentum with a 27% gain in the last month alone. Notwithstanding the latest gain, the annual share price re
Sanyuan Biotech (301206.SZ) announced first-quarter results, net profit of 24.2477 million yuan, an increase of 210.54% year-on-year
Sanyuan Biotech (301206.SZ) released its report for the first quarter of 2024. The company's revenue was 192 million yuan...
Shandong Sanyuan Biotechnology Co.,Ltd.'s (SZSE:301206) Secretary Zaijian Nie Is the Most Upbeat Insider, and Their Holdings Increased by 8.3% Last Week
Key Insights Insiders appear to have a vested interest in Shandong Sanyuan BiotechnologyLtd's growth, as seen by their sizeable ownership A total of 2 investors have a majority stake in the company
Sanyuan Biotech (301206.SZ) received a warning letter from the Shandong Securities Regulatory Bureau
Sanyuan Biotech (301206.SZ) announced that the company received China Securities Regulatory Administration on February 29, 2024...
Sanyuan Biotech (301206.SZ) actual controller Nie Zaijian and general manager Cheng Baohua completed an increase of 430,200 shares
Sanyuan Biotech (301206.SZ) announcement. As of the disclosure date of this announcement, the company's controlling shareholders, actual controllers, directors...
Sanyuan Biology (301206.SZ): Currently, the production capacity of alloone sugar can no longer meet customer needs, and the company is in the process of expanding production
Gelonghui, Feb. 20 | Sanyuan Biotech (301206.SZ) said on the investor interactive platform that the company's main products are erythritol, allodonose and its compound sugar. Currently, the annual production capacity of erythritol is 135,000 tons, and the annual production capacity of allodonose is 2,000 tons (3,000 tons of liquid). Currently, the production capacity of alloone sugar can no longer meet customer needs, and the company is in the process of expanding production.
Sanyuan Biotech (301206.SZ): The chairman and executives have increased their holdings by a total of 230.26 million shares
Gelonghui, Feb. 7 | Sanyuan Biotech (301206.SZ) announced that as of the disclosure date, the controlling shareholder, actual controller, chairman and senior management increased their holdings by a total of 2302.64 million shares through the Shenzhen Stock Exchange trading system through centralized bidding, accounting for 0.1138% of the company's current total share capital. The total increase amount was RMB 5,324,536.31.
Sanyuan Biotech (301206.SZ): Chairman and some senior management plan to increase the company's shares by 8.5 million yuan to 11 million yuan
Gelonghui, Feb. 6, 丨 Sanyuan Biotech (301206.SZ) announced that the controlling shareholder, actual controller, and chairman of Shandong Sanyuan Biotechnology Co., Ltd. (accounting for 45.94% of the company's current total share capital); Mr. Cheng Baohua, general manager, who holds 2,028,000 shares of the company (1.00% of the company's current total share capital), plans to use its own capital within 6 months from the date of disclosure of this announcement The system uses centralized bidding transactions or
Sanyuan Biotech (301206.SZ): Net profit is expected to drop 62.12% — 70.68% year-on-year in 2023
On January 29, Gelonghui | Sanyuan Biotech (301206.SZ) announced that net profit for 2023 is expected to be 48 million yuan to 62 million yuan, down 62.12% to 70.68% from the same period last year, after deducting non-net profit of 47 million yuan to 60 million yuan, down 63.04% to 71.05% from the same period last year. The decline in the company's business performance in 2023 was mainly affected by factors such as increased competition in the erythritol industry and the slowdown in demand growth from downstream customers. The price war that continued throughout the year had a significant impact on the company's sales revenue and gross margin. Although the company voluntarily withdrew from vicious competition,
Huaan Securities: The new functional sugar substitute market is expected to bring investment opportunities in the industrial chain from 0-1
The process of the new functional sugar substitute market from 0-1 is expected to bring investment opportunities in the industrial chain.
Sanyuan Biotech (301206.SZ): Currently, the company's high-quality stevia is mainly used in the production of its own blended sugar
Gelonghui January 12 丨 Sanyuan Biology (301206.SZ) recently received a survey on specific subjects. Regarding “What are the characteristics and advantages of high-quality stevia (rebaudioside M)?” The company replied that compared with ordinary steviol glycosides, high-quality stevia removes bitterness, improves the taste significantly, and can be used in beverages. Furthermore, as a high sweetener, compared with synthetic products such as sucralose and aspartame, high-quality stevia is a natural sugar substitute and can better meet the health needs of high-end consumers. Most of the high-end blends in the EU market use steviol glycosides, and high-quality stevia without a bitter aftertaste will be more popular. eye
Sanyuan Biology (301206.SZ): Currently, products combining alloone sugar, erythritol, and high sweeteners are already very active in the US
Gelonghui, January 12丨Sanyuan Biotech (301206.SZ) was recently surveyed by specific subjects on “How does the company view the alloone sugar market?” The company replied that as a new type of sugar substitute, aloxone sugar has not been widely used in the market, and manufacturers are already very motivated to participate. Currently, everyone's process technology is not mature, and they are in the process of adjusting and changing. In the future, whoever has good quality, low cost, and stable supply will win the favor of customers. Currently, products combining allodonose, erythritol, and high-power sweeteners are already very active in the US. The quality of the company's aloxone sugar crystals was also obtained
Sanyuan Biotech (301206.SZ): The number of registered shareholders of the company as of December 29 was 16,187
On January 12, Gelonghui | Sanyuan Biotech (301206.SZ) said on the investor interactive platform that as of December 29, the number of registered shareholders of the company was 16,187.
Ternary Biology (301206.SZ): Technical patents related to the preparation of tag sugar are being applied
On December 7, Glonghui, on December 7, some investors asked Sanyuan Biotech (301206.SZ) on the investor interactive platform, “The activity record sheet mentions overcoming technology that uses starch to prepare tagger sugar. Have you applied for a patent? Are there any patent applications? Are there any patent barriers high?” The company replied that technical patents related to the company's preparation of tag sugar are being applied for.
Analysis
Price Target
No Data
